Connor, Clark & Lunn Investment Management Ltd. Cullinan Oncology, Inc. Transaction History
Connor, Clark & Lunn Investment Management Ltd.
- $21.8 Billion
- Q1 2024
A detailed history of Connor, Clark & Lunn Investment Management Ltd. transactions in Cullinan Oncology, Inc. stock. As of the latest transaction made, Connor, Clark & Lunn Investment Management Ltd. holds 36,401 shares of CGEM stock, worth $593,700. This represents 0.0% of its overall portfolio holdings.
Number of Shares
36,401Holding current value
$593,700% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding CGEM
# of Institutions
118Shares Held
42.8MCall Options Held
12.6KPut Options Held
4.9K-
Bio Impact Capital LLC Cambridge, MA7.65MShares$125 Million21.33% of portfolio
-
Chi Advisors LLC New York, NY3.41MShares$55.7 Million15.23% of portfolio
-
Bvf Inc San Francisco, CA3.2MShares$52.1 Million1.63% of portfolio
-
Blue Owl Capital Holdings LP New York, NY2.92MShares$47.7 Million13.21% of portfolio
-
Franklin Resources Inc San Mateo, CA2.7MShares$44 Million0.02% of portfolio
About Cullinan Oncology, Inc.
- Ticker CGEM
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 45,612,200
- Market Cap $744M
- Description
- Cullinan Oncology Inc., a biopharmaceutical company, focuses on developing a pipeline of targeted oncology and immuno-oncology therapies for cancer patients in the United States. The company's lead candidate is the CLN-081, an orally available small molecule that is in a Phase I/IIa dose escalation and expansion trial for treating patients with ...